



Roche Group early-stage development pipeline

PHASE I (37 NMEs)			PHASE II (15 NMEs)		
ONCOLOGY (14 NMEs) ABT-263/Bcl-2 (RG7433) <ul style="list-style-type: none">Solid tumors and hematologic malignancies Anti-EGFL7 (RG7414) <ul style="list-style-type: none">Solid tumors Anti-NRP1 (RG7347) <ul style="list-style-type: none">Solid tumors Anti-PIGF (RG7334) <ul style="list-style-type: none">Solid tumors CKI27 (RG7304) <ul style="list-style-type: none">Solid tumors Dulanermin (RG3639) <ul style="list-style-type: none">Colorectal cancer G-secretase Inh (RG4733) <ul style="list-style-type: none">Solid tumors huMAb EGFR/GA201 (RG7160) <ul style="list-style-type: none">Head and neck squamous cell carcinomaNon-small cell lung cancer <ul style="list-style-type: none">Solid tumors huMAb Glypican-3/GC33¹ <ul style="list-style-type: none">Hepatocellular (liver) carcinoma MDM2 Antagonist (RG7112) <ul style="list-style-type: none">Solid tumors and hematologic malignancies MEK Inh/CIF (RG7167) <ul style="list-style-type: none">Solid tumors MEK Inh/GDC-0973 (RG7420) <ul style="list-style-type: none">Solid tumors NME (RG7440) <ul style="list-style-type: none">Solid tumors PI3 Kinase Inh/GDC-0941 (RG7321) <ul style="list-style-type: none">Metastatic breast cancerMetastatic NSCLC PI3K/mTOR Inh/GDC-0980 (RG7422) <ul style="list-style-type: none">Solid tumors and NHL	INFLAMMATION (4 NMEs) Anti-LT α (RG7416) <ul style="list-style-type: none">Rheumatoid arthritis huMAb IL-17 (RG4934) <ul style="list-style-type: none">Psoriatic arthritis rhuMAb-β7 (RG7413) <ul style="list-style-type: none">Ulcerative colitis VAP-1 Antibody² <ul style="list-style-type: none">Rheumatoid arthritisPlaque psoriasis VIROLOGY (2 NME) Nitazoxamide³ <ul style="list-style-type: none">Chronic hepatitis C Serine Palmitoyltransferase Inh/NA808³ <ul style="list-style-type: none">Chronic hepatitis C METABOLIC (8 NMEs) 11 Beta HSD Inh (RG4929) <ul style="list-style-type: none">Type 2 diabetes 11 Beta HSD Inh (RG7234) <ul style="list-style-type: none">Type 2 diabetes ABCA1 Inducer (RG7273) <ul style="list-style-type: none">Dyslipidemia Anti-oxLDL (RG7418) <ul style="list-style-type: none">Secondary prevention of cardiovascular events BHT-3021 (RG7426) <ul style="list-style-type: none">Type I diabetes C-Raf Inh/PLX5568 (RG7376) <ul style="list-style-type: none">Polycystic kidney disease P-selectin huMAb (RG1512) <ul style="list-style-type: none">Peripheral vascular disease Y2R Agonist Peptide (RG7089) <ul style="list-style-type: none">Type 2 diabetes	CNS (8 NMEs) Anti-Aβ (RG7412) <ul style="list-style-type: none">Alzheimer's disease Gantenerumab/Anti-Aβ (RG1450) <ul style="list-style-type: none">Alzheimer's disease GABA-A Agonist (RG1662) <ul style="list-style-type: none">Alzheimer's disease NMDA Antagonist⁴ <ul style="list-style-type: none">Treatment Resistant Depression mGluR2 Antagonist (RG1578) <ul style="list-style-type: none">Depression PEG IGF-1 (RG7010) <ul style="list-style-type: none">Neurodegeneration amyotrophic lateral sclerosis TAAR1 Part Agonist (RG7351) <ul style="list-style-type: none">Depression Triple Reuptake Inh (RG7166) <ul style="list-style-type: none">Depression OPHTHALMOLOGY (1 NME) Anti-Factor D (RG7417) <ul style="list-style-type: none">Geographic atrophy associated with age-related macular degeneration	ONCOLOGY (4 NMEs) ABT-263/Bcl-2 (RG7433) <ul style="list-style-type: none">Relapsed chronic lymphocytic leukaemiaRelapsed lymphoid malignanciesSmall cell lung cancer Avastin <ul style="list-style-type: none">1L metastatic melanoma BRAF Inh/PLX4032 (RG7204) <ul style="list-style-type: none">2L & 3L metastatic melanoma GA101/Anti-CD20 (RG7159) <ul style="list-style-type: none">Chronic lymphocytic leukaemiaNon-Hodgkin's Lymphoma Hedgehog Pathway Inh/GDC-0449 (RG3616) <ul style="list-style-type: none">Advanced basal cell carcinoma1L metastatic colorectal cancerOvarian cancer MetMab (RG3638) <ul style="list-style-type: none">2L & 3L metastatic NSCLC Pertuzumab <ul style="list-style-type: none">Neoadjuvant HER2+ breast cancer2L HER2+ metastatic breast cancer T-DM1 (RG3502) <ul style="list-style-type: none">1L HER2+ metastatic breast cancer3L HER2+ metastatic breast cancer T-DM1 (RG3502) + pertuzumab (RG1273) <ul style="list-style-type: none">HER2+ metastatic breast cancer Topoisomerase I Inh/TP300¹ <ul style="list-style-type: none">Colorectal cancer	INFLAMMATION (4 NMEs) huMAb OX40L (RG4930) <ul style="list-style-type: none">Asthma Lebrikizumab/Anti-IL13 (RG3637) <ul style="list-style-type: none">Asthma Palovarotene (RG667) <ul style="list-style-type: none">Emphysema Rontalizumab/Anti-IFNα (RG7415) <ul style="list-style-type: none">Systemic lupus erythematosus Xolair <ul style="list-style-type: none">Chronic idiopathic urticaria VIROLOGY (3 NMEs) HPV16 (RG3484) <ul style="list-style-type: none">Cervical neoplasia Nucleoside Analogue Polymerase Inh (RG7128) <ul style="list-style-type: none">Chronic hepatitis C Protease Inh (RG7227) <ul style="list-style-type: none">Chronic hepatitis C METABOLIC (1 NMEs) SGLT2 Inhibitor (RG7201) <ul style="list-style-type: none">Type 2 diabetes	CNS (3 NMEs) GlyT1 Inh (RG1678) <ul style="list-style-type: none">Schizophrenia mGluR5 Antagonist (RG7090) <ul style="list-style-type: none">Treatment Resistant DepressionFragile X Syndrome Nicotinic α7 Agonist (RG3487) <ul style="list-style-type: none">Alzheimer's disease Ocrelizumab (RG1594) <ul style="list-style-type: none">Relapsing remitting multiple sclerosis

As of 15 April 2010

¹ Opt-in opportunity from Chugai; ² Opt-in opportunity from Biotie; ³ Participation through Chugai; ⁴ Buy-back opportunity from Evotec.



Roche Group late-stage development pipeline

PHASE III (8 NMEs)

ONCOLOGY (4 NMEs)

Avastin

- 1L advanced gastric cancer¹
- 1L HER2- metastatic breast cancer
- 1L HER2+ metastatic breast cancer
- 2L HER2- metastatic breast cancer
- Adjuvant colon cancer
- Adjuvant HER2- breast cancer
- Adjuvant HER2+ breast cancer
- Adjuvant non-small cell lung cancer
- Diffuse large B-cell lymphoma
- Front-line ovarian cancer
- High risk carcinoid
- Hormone refractory prostate cancer¹
- Newly diagnosed glioblastoma multiforme
- Relapsed platinum-sensitive ovarian cancer

Avastin +/- Tarceva

- 1L maintenance advanced NSCLC

BRAF Inh/PLX4032 (RG7204)

- 1L metastatic melanoma

GA101/Anti-CD20 (RG7159)

- Front-line chronic lymphocytic leukaemia

Herceptin

- Adjuvant HER2+ breast cancer (HERA 2-year)
- Subcutaneous formulation in HER2+ breast cancer

Pertuzumab (RG1273)

- 1L HER2+ metastatic breast cancer

Tarceva

- Adjuvant NSCLC
- 1L metastatic EGFR mutant+ NSCLC

Trastuzumab-DM1 (RG3502)

- 2L HER2+ metastatic breast cancer

Xeloda

- Adjuvant breast cancer

INFLAMMATION (1 NME)

Ocrelizumab (RG1594)

- Rheumatoid arthritis

Rituxan

- ANCA-associated vasculitis

RoActemra/Actemra

- Early rheumatoid arthritis
- Systemic juvenile idiopathic arthritis (sJIA)

Xolair

- Asthma

METABOLIC (3 NMEs)

Aleglitazar (RG1439)

- Type 2 diabetes (CV risk reduction)

Dalcetrapib (RG1658)

- Atherosclerosis (CV risk reduction)

Taspoglutide (RG1583)

- Type 2 diabetes

OTHERS

TNKase

- Central venous catheter clearance
- Hemodialysis catheter clearance

OPHTHALMOLOGY

Lucentis

- Diabetic macular edema
- High-dose in AMD

AWAITING REGULATORY APPROVAL (1 NMEs)

ONCOLOGY

- Avastin for 1L HER2- metastatic breast cancer²
- MabThera/Rituxan for maintenance treatment of 1L advanced follicular lymphoma
- Tarceva for 1L maintenance therapy for advanced NSCLC

INFLAMMATION

- Eldercalcitol/ED-71⁴ for osteoporosis
- MabThera for rheumatoid arthritis MTX inadequate responders³
- RoActemra/Actemra for PJD in rheumatoid arthritis
- Xolair for pediatric asthma⁵

VIROLOGY

- Valcyte for prevention of CMV disease in high-risk kidney transplant patients; extended dosing⁶

OPHTHALMOLOGY

- Lucentis for retinal vein occlusion⁶

OTHERS

- EPOCH⁴ for chemo induced anaemia

US FDA REGULATORY SUBMISSION PENDING

ONCOLOGY

- Herceptin for HER2+ advanced gastric cancer⁷
- Xeloda for adjuvant colon cancer; combo with oxaliplatin⁷

As of 15 April 2010

Unless stated otherwise, regulatory submissions occurred in both US and EU. ¹The Phase III trial did not meet its primary endpoint. Next steps under evaluation. ²RIBBON-1 and AVDO convert to full approval in the US; RIBBON-1 awaiting EMA approval. ³EMA submission. ⁴Participation through Chugai. ⁵We received a Complete Response Letter from the FDA in December 2009 and are currently evaluating our next steps. ⁶U.S. FDA submission. ⁷Approved in the EU.